title: [Longjintonglin Capsules for type IIIA prostatitis accompanied by abnormal semen liquefaction: A clinical observation].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of Longjintonglin Capsules on type IIIA prostatitis accompanied by abnormal semen liquefaction.
  
  
  METHODS
  We selected 140 patients with type IIIA prostatitis accompanied by abnormal semen liquefaction according to the diagnostic standards of the American Institutes of Health (NIH) and treated them with Longjintonglin Capsules orally 3 capsules once tid for 12 weeks. We obtained the NIH Chronic Prostatitis Symptom Indexes (NIH-CPSI), traditional Chinese medicine (TCM) syndrome scores, leukocyte count in the expressed prostatic secretion (EPS), semen liquefaction time, and the results of semen analysis and compared these indicators before and after the treatment.
  
  
  RESULTS
  Of the 140 cases, 132 were included in this study, excluding 8 due to their incomplete case histories. Before and after 4, 8 and 12 weeks of medication, the total NIH-CPSI scores were 24.52 ± 5.43, 21.28 ± 4.85, 18.01 ± 4.28, and 14.49 ± 3.65 (P < 0.01), the TCM syndrome scores were 35.63 ± 6.07, 26.66 ± 5.03, 17.37 ± 4.18, and 11.11 ± 3.96 (P < 0.01), and the leukocyte counts (/HP) were 27.50 ± 7.01, 22.38 ± 5.22, 16:76 ± 4.10, and 11.40 ± 4.74 (P < 0.01), respectively. After 12 weeks of treatment, 31 of the patients with type IIIA prostatitis were cured and another 72 well responded, with an overall response rate of 78.0%. Of those with abnormal semen liquefaction, 61 were cured, 39 well responded, and 32 failed to respond, with an overall effectiveness rate of 75.8%. Semen analysis showed significantly increased percentage of progressively motile sperm after 4, 8 and 12 weeks of medication as compared with the baseline (P < 0.01). No abnormal liver or renal function or other adverse reactions were observed during the treatment.
  
  
  CONCLUSIONS
  Longjintonglin Capsules, with its advantages of safety, effectiveness and no obvious adverse effects, deserve to be recommended for the treatment of type IIIA prostatitis accompanied by abnormal semen liquefaction.
authors.forename: Hong-cai
authors.initials: HC
authors.lastname: Cai
authors.forename: Chang-chun
authors.initials: CC
authors.lastname: Wan
authors.forename: Qiang
authors.initials: Q
authors.lastname: Geng
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Guo-wei
authors.initials: GW
authors.lastname: Zhang
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Shang
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Huang
mesh_terms: D002214:Capsules; D004365:Drugs, Chinese Herbal; D006801:Humans; D008297:Male; D008516:Medicine, Chinese Traditional; D008517:Phytotherapy; D011472:Prostatitis / Q000145:classification / Q000188:drug therapy*; D012661:Semen; D055101:Semen Analysis
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal